enGene TherapeuticsENGN
Recorded

enGene Therapeutics Study update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration50 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome to the enGene Therapeutics webinar to discuss new data from its LEGEND trial and provide a regulatory update. At this time, all attendees are in a listen-only mode, and a question-and-answer session will follow the formal presentation. As a reminder, this call is being recorded, and a replay will be made available on the enGene website following the conclusion of the event. I'd now like to turn the call over to Lauren Hopfer, Executive Director of Investor Relations at enGene Therapeutics. Please go ahead, Lauren. Thank you.

Lauren HopferExecutive Director of Investor Relations

Good afternoon, everyone, and thank you for joining. With me from enGene on today's call are Ron Cooper, Chief Executive Officer, Amy Pott, Chief Global Commercialization Officer, and we are pleased to welcome the LEGEND trial's primary investigator, Dr. Ashish Kamat, Endowed Professor of Urologic Oncology and Cancer Research at MD Anderson Cancer Center. Before we begin, I would like to remind you that during our prepared remarks and Q&A session to follow, we may make forward-looking statements for purposes of U.S. and Canadian securities laws, and we draw your attention to the disclaimer on the slides that accompany this presentation. At this time, I will turn the call over to Ron Cooper, enGene's President and CEO.

Ron CooperCEO

Ron? All right, great. Well, thanks, Lauren, and thank you all for joining us this afternoon on short notice.

Ron CooperCEO

Here on slide three is a quick overview of this afternoon's agenda. After the market closed today, we're pleased to report updated data from LEGEND's pivotal cohort one, studying our lead- Its tolerability profile continues to trend as potentially best in class, with the lowest rates of discontinuations or interruptions due to treatment-related adverse events, and our primary endpoint, complete response at any time, is 56%, is squarely within the range of approved therapies. Durability, which was very immature during our last update, is also trending towards the range of approved products.

Ron CooperCEO

Importantly, during our pre-BLA meeting with the FDA this quarter, we reached alignment on key components of our statistical analysis plan, including the efficacy of valuable patient population for cohort one, as well as our plan to initiate a BLA submission for detalimogene before year-end, positioning detalimogene for potential approval in 2027. In tandem with our data and regulatory update, we also issued news that we've appointed a new Chief Medical Officer, Dr. Erik Goluboff, and Chief Legal and Administrative Officer, Jason Duncan, both of whom will play key roles as we enter our next phase of company growth and prepare for potential commercialization. Welcome, Jason, and welcome, Erik. This is an exciting time for our company and for the NMIBC space. With the advent of new treatment options, the sequencing of bladder-sparing therapies will drive market growth by expanding the treatable population.

Ron CooperCEO

We're already seeing this play out with earlier approved products, and seeing continued growth, even with the advent of new product launches. When sequencing therapies, urologists are looking for different approaches, and detalimogene's unique non-viral MOA could provide them a different treatment option. As we highlighted in our KOL webinar last month, treatment selection is nuanced through the patient journey with high-risk NMIBC, and it is never a one-size-fits-all model. As the prevalent population continues to grow, this will not be a winner-take-all market. We continue to believe that as a next-gen therapy, detalimogene, with its unique non-viral attributes and MOA, low-cost scalable manufacturing, favorable tolerability, and in-class efficacy, would be uniquely positioned to unlock sequencing more broadly across community urology segments.

Ron CooperCEO

75% of NMIBC patients are being treated in community practice settings, where urologists must weigh a variety of factors when selecting treatment, from logistical and infrastructure challenges to financial considerations. If approved, detalimogene would be the first and only non-viral plasmid gene therapy approved for NMIBC and truly suitable for all practice settings. The potential to stock and store detalimogene in a standard freezer or fridge, the lack of BSL-2 handling or post-treatment precautions, and its streamlined preparation and administration help remove logistical and infrastructure challenges across the board. With that, I'm pleased to turn the call over to Dr. Ashish Kamat to review the latest data from LEGEND Cohort 1.

Ron CooperCEO

Dr. Kamat is Endowed Professor of Urologic Oncology and Cancer Research at the University of Texas MD Anderson Cancer Center, President of the International Bladder Cancer Group, Co-President of the International Bladder Cancer Network, and primary investigator for our LEGEND trial.

Ashish KamatEndowed Professor of Urologic Oncology and Cancer Research

Dr. Kamat? Thank you for that introduction, Ron, and thanks everyone for joining us this afternoon.

Ashish KamatEndowed Professor of Urologic Oncology and Cancer Research

I will be reviewing the latest interim results from the pivotal cohort of LEGEND, evaluating detalimogene voraplasmid in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, both with and without concomitant papillary disease. The treatment landscape for BCG-unresponsive non-muscle invasive bladder cancer has substantially changed over the past several years. We now have several bladder-preserving options, which is welcome progress, of course. But as someone who treats patients with bladder cancer every day, I can tell you we still have a considerable unmet need. Radical cystectomy remains an important curative option, yet many patients are unwilling or unable to undergo it. For those patients, our challenge is to find treatments that provide meaningful and durable disease control while minimizing toxicity and disruption to their lives.

Ashish KamatEndowed Professor of Urologic Oncology and Cancer Research

And this is where practical considerations become very important. How often does the patient need treatment? How well can they tolerate it? Can their urologist administer it in their own practice, or will they need to refer the patient to a specialized center? These are conversations that we have with our patients every day, and they provide an important clinical context for evaluating the LEGEND data. As a reminder, the LEGEND trial is an ongoing phase II study. The pivotal cohort enrolled 125 patients with BCG-unresponsive NMIBC with CIS, with or without high-grade Ta or T1 disease, who are ineligible for or elected not to undergo cystectomy. Detalimogene is administered intravesically by a catheter with a 60-minute dwell time. The regimen operates on 12-week treatment cycles, with dosing on week one, two, five, six of each cycle.

Ashish KamatEndowed Professor of Urologic Oncology and Cancer Research

A reinduction cycle is permitted at week 12 for patients with persistent or recurrent disease, as specified in the protocol. Patients in a CR at the 48-week disease assessment, or 12-month landmark assessment, then move into a maintenance phase, during which they receive detalimogene on week one and two of each 12-week cycle for up to 36 months. The primary endpoint is complete response, or CR, at any time. Key secondary endpoints include duration of response, the proportion of responders maintaining response for at least 12 months, landmark complete response rates at three, six, nine, and 12 months, safety, and progression-free outcomes. The broader program also includes cohorts that may inform use across additional high-risk NMIBC settings. Something I believe is important to this dataset is that the pivotal cohort population is highly reflective of what we are now seeing in the BCG-unresponsive setting.

Ashish KamatEndowed Professor of Urologic Oncology and Cancer Research

40% had concomitant papillary disease, and notably, 26% of patients had received treatment beyond BCG, including intravesical chemotherapy, other viral gene therapies, and systemic immunotherapy. Overall, this patient population is more resistant than some of the earlier NMIBC pivotal studies. Importantly, more than 30% of patients declined cystectomy rather than being medically ineligible, and this highlights the strong patient preference for bladder preservation and the need for additional bladder-sparing alternatives. These are the kinds of patients we increasingly see in our practice. One important development since our previous update is the clarification of the efficacy-evaluable population following discussions with the FDA. Of the 125 enrolled patients, 120 are included in the current efficacy analyses, with five excluded for pre-specified reasons under the agreed analysis approach. The analysis population and statistical approach have been discussed with the FDA.

Ashish KamatEndowed Professor of Urologic Oncology and Cancer Research

The exclusions are few and based on one patient withdrawing from study before assessment, two patients who did not receive adequate BCG dosing, and two patients who do not have CIS within one year of receiving adequate BCG. All the data presented today will reflect the FDA-aligned efficacy-evaluable population. Now, turning to efficacy, the primary endpoint is anytime CR rate, which is 66%. Relative to the prior update, which I presented at the AUA in May of this year, we see a 2% improvement, which puts detalimogene squarely in the range observed across approved therapies in this setting. Cross-trial comparisons have limitations, so the relevant point here is not that one bar is higher than the other, but that detalimogene has demonstrated meaningful activity in a challenging, previously treated population. On the right, you can see, of patients who achieved a CR, 91% occurred at first disease assessment.

Ashish KamatEndowed Professor of Urologic Oncology and Cancer Research

100% of responders were free from bladder cancer that progressed to T2 or greater, and 96% of responders remain cystectomy-free. Across the entire efficacy-evaluable population, 97% of patients were free from progression to T2 or greater disease, and 86% remain free from cystectomy. This data clearly shows detalimogene may offer a reasonable chance of complete response, which can be determined quickly and with low risk of progression to our patients. These are outcomes that matter when discussing bladder preservation with patients. Perhaps the most important question after achieving a CR is how long that response lasts. An initial response is, of course, encouraging, but sustained disease control is what allows us to preserve the bladder safely over time. Here, we can see the updated duration of response data.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day